NURS 617 Exam 1 – Questions & Accurate Solutions
(McNeese State University)
Save Groups
Terms in this set (118)
Thrombolytic agent used for acute Alteplase (tPA)
ischemic stroke, MI, or PE Reteplase (Retavase)
Tenecteplase (TNKase)
Act in different ways but the end result Pharmacodynamics of
is to activate the body's own Alteplase (tPA)
plasminogen protein into the natural Reteplase (Retavase)
clot-lysing compound plasminogen Tenecteplase (TNKase)
This promotes dissolution of already
formed clots (for instance clots in the
coronary arteries)
Administered IV and metabolized in Pharmacokinetics of
the liver Alteplase (tPA)
Reteplase (Retavase)
Tenecteplase (TNKase)
,Rapid dissolution of fresh clots Advantages of
allowing survival of ischemic Alteplase (tPA)
myocardium and preventing loss of Reteplase (Retavase)
myocardial tissues Tenecteplase (TNKase)
Short half-life (about 5 minutes)-
advantage with adverse effects
Prevents the extension of the
infarction in MI patients, allowing
reperfusion of ischemic myocardium
and prevention of additional areas of
myocardial cell death
Bleeding: will dissolve some wanted Disadvantages of
clots and provoke bleeding from sites Alteplase (tPA)
other than the coronary arteries Reteplase (Retavase)
Tenecteplase (TNKase)
Very short half-life which can lead to a
high re-thrombosis rate (20%) when
the drug is discontinued unless an
antithrombotic drug (heparin) is used
concurrently
Possible hypotension leading to a
sudden decrease in coronary
perfusion
Contraindicated in active bleeding
states
,Antihypertensive drugs to avoid in ACE inhibitors- considered teratogenic and toxic
pregnancy
ARBs (Angiotensin II Receptor Blockers) - increased
incidence of fetal death especially in the 2nd and 3rd
trimester
Limited studies of nifedipine (CCB) in pregnancy; as a
class, CCBs not considered safe for use in pregnancy.
This should be taken into consideration in planning
long-term antihypertensive therapy in a woman
trying to get pregnant
Between neonates and adults who has Neonates - due to thinner skin and higher surface
a faster absorption of topical area-to-body weight ratio
medications?
Block both beta 1 and beta 2 Main therapeutic action of non-selective beta
receptors, reducing heart rate, blockers
myocardial contractility, and blood
pressure
, Antagonists to the neurotransmitters Pharmacodynamics of non-selective beta blockers
(norepinephrine and epinephrine) on
both beta 1 and beta 2 adrenergic
receptors.
Blocking beta 1 receptors in the heart
slows the heart rate and decreases
myocardial contractility of the heart,
decreasing cardiac output and blood
pressure.
Blockade of other beta 1 receptors
reduces production of intraocular
fluid from the ciliary body of the eye
to decrease intraocular pressure
(therapeutic in patients with either
open-angle or closed-angle
glaucoma) and decreases beta 1
mediated CNS stimulation treating
mild anxiety like stage fright.
Blockade of beta 2 receptors in the
lungs and in the peripheral muscular
arteries is not a therapeutic action but
is responsible for many of the adverse
effects of these drugs
(McNeese State University)
Save Groups
Terms in this set (118)
Thrombolytic agent used for acute Alteplase (tPA)
ischemic stroke, MI, or PE Reteplase (Retavase)
Tenecteplase (TNKase)
Act in different ways but the end result Pharmacodynamics of
is to activate the body's own Alteplase (tPA)
plasminogen protein into the natural Reteplase (Retavase)
clot-lysing compound plasminogen Tenecteplase (TNKase)
This promotes dissolution of already
formed clots (for instance clots in the
coronary arteries)
Administered IV and metabolized in Pharmacokinetics of
the liver Alteplase (tPA)
Reteplase (Retavase)
Tenecteplase (TNKase)
,Rapid dissolution of fresh clots Advantages of
allowing survival of ischemic Alteplase (tPA)
myocardium and preventing loss of Reteplase (Retavase)
myocardial tissues Tenecteplase (TNKase)
Short half-life (about 5 minutes)-
advantage with adverse effects
Prevents the extension of the
infarction in MI patients, allowing
reperfusion of ischemic myocardium
and prevention of additional areas of
myocardial cell death
Bleeding: will dissolve some wanted Disadvantages of
clots and provoke bleeding from sites Alteplase (tPA)
other than the coronary arteries Reteplase (Retavase)
Tenecteplase (TNKase)
Very short half-life which can lead to a
high re-thrombosis rate (20%) when
the drug is discontinued unless an
antithrombotic drug (heparin) is used
concurrently
Possible hypotension leading to a
sudden decrease in coronary
perfusion
Contraindicated in active bleeding
states
,Antihypertensive drugs to avoid in ACE inhibitors- considered teratogenic and toxic
pregnancy
ARBs (Angiotensin II Receptor Blockers) - increased
incidence of fetal death especially in the 2nd and 3rd
trimester
Limited studies of nifedipine (CCB) in pregnancy; as a
class, CCBs not considered safe for use in pregnancy.
This should be taken into consideration in planning
long-term antihypertensive therapy in a woman
trying to get pregnant
Between neonates and adults who has Neonates - due to thinner skin and higher surface
a faster absorption of topical area-to-body weight ratio
medications?
Block both beta 1 and beta 2 Main therapeutic action of non-selective beta
receptors, reducing heart rate, blockers
myocardial contractility, and blood
pressure
, Antagonists to the neurotransmitters Pharmacodynamics of non-selective beta blockers
(norepinephrine and epinephrine) on
both beta 1 and beta 2 adrenergic
receptors.
Blocking beta 1 receptors in the heart
slows the heart rate and decreases
myocardial contractility of the heart,
decreasing cardiac output and blood
pressure.
Blockade of other beta 1 receptors
reduces production of intraocular
fluid from the ciliary body of the eye
to decrease intraocular pressure
(therapeutic in patients with either
open-angle or closed-angle
glaucoma) and decreases beta 1
mediated CNS stimulation treating
mild anxiety like stage fright.
Blockade of beta 2 receptors in the
lungs and in the peripheral muscular
arteries is not a therapeutic action but
is responsible for many of the adverse
effects of these drugs
